Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
The Ethereum spot ETF experienced a total net outflow of 13.517 million US dollars yesterday, with the ETF net asset ratio reaching 2.32%

The Ethereum spot ETF experienced a total net outflow of 13.517 million US dollars yesterday, with the ETF net asset ratio reaching 2.32%

Bitget2024/08/20 04:25

According to SoSoValue data, yesterday (Eastern Time August 19), the net outflow of Ethereum spot ETF was $13.517 million. Yesterday, Grayscale's Ethereum Trust ETF ETHE had a single-day net outflow of $20.3032 million, and the current historical net outflow of ETHE is $2.435 billion. Grayscale's Mini Ethereum Trust ETF ETH had a single-day net inflow of $4.9152 million, and the total historical net inflow for Grayscale's Mini Ethereum Trust ETH is currently at $228 million.

As of press time, the Net Asset Value (NAV) for Ethereum spot ETFs stands at $7.297 billion with an NAV ratio (market value as a percentage of total market cap) reaching 2.32%. The cumulative historical net outflows have reached up to $434 million.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

On Monday, storage chip concept stocks generally rose, with SanDisk (SNDK.US) up by 6%.

智通财经2026/08/17 13:51
U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds

On August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 study of Enhertu (trastuzumab deruxtecan) as a monotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has achieved highly positive results.

智通财经2026/08/17 12:56
AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds